Bruker Co. (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Analysts

Bruker Co. (NASDAQ:BRKR) has been given an average recommendation of “Hold” by the ten analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $74.30.

Several research firms recently weighed in on BRKR. Citigroup boosted their target price on Bruker from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 3rd. SVB Leerink boosted their price objective on Bruker from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, September 9th. Wells Fargo & Company boosted their price objective on Bruker from $85.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 2nd. Finally, Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a research note on Tuesday, September 28th.

Shares of Bruker stock traded down $0.37 on Friday, reaching $77.30. 655,053 shares of the company were exchanged, compared to its average volume of 591,219. The stock’s 50 day moving average price is $80.12 and its 200-day moving average price is $78.95. The company has a market cap of $11.72 billion, a P/E ratio of 43.67, a price-to-earnings-growth ratio of 1.95 and a beta of 1.25. Bruker has a 1-year low of $50.00 and a 1-year high of $92.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.16 and a quick ratio of 1.36.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 1st. The medical research company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.19. The firm had revenue of $608.90 million during the quarter, compared to analysts’ expectations of $575.33 million. Bruker had a return on equity of 31.48% and a net margin of 11.44%. The firm’s revenue was up 19.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 earnings per share. On average, research analysts predict that Bruker will post 2.09 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 17th. Stockholders of record on Wednesday, December 1st will be issued a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date is Tuesday, November 30th. Bruker’s payout ratio is currently 9.04%.

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp grew its holdings in Bruker by 35.9% in the second quarter. State Street Corp now owns 2,050,445 shares of the medical research company’s stock valued at $155,793,000 after purchasing an additional 541,579 shares during the last quarter. Mirabella Financial Services LLP acquired a new stake in Bruker in the second quarter valued at $4,695,000. Ergoteles LLC acquired a new stake in Bruker in the second quarter valued at $1,315,000. Fuller & Thaler Asset Management Inc. grew its holdings in Bruker by 2.9% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 1,864,899 shares of the medical research company’s stock valued at $141,695,000 after purchasing an additional 51,993 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in Bruker in the second quarter valued at $3,096,000. 68.95% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST).

Recommended Story: What is the S&P/ASX 200 Index?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.